Takeda To Help Develop Lundbeck’s First-In-Class Mood Disorder Candidates In Japan, U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal includes $40 million upfront payment and potential $345 million in milestones for Lundbeck.
You may also be interested in...
Lundbeck/Takeda Advance Novel Anxiety Candidate To Phase III
H. Lundbeck and Takeda Pharmaceutical have initiated Phase III trials of their novel mood and anxiety disorders candidate Lu AA21004 roughly four months after inking a co-development deal, the firms announced Dec. 18
Lundbeck/Takeda Advance Novel Anxiety Candidate To Phase III
Milestone garners Danish firm $40 million four months into collaboration with Takeda.
Lundbeck/Takeda Advance Novel Anxiety Candidate To Phase III
Milestone garners Danish firm $40 million four months into collaboration with Takeda.